ORIGINAL ARTICLE

Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials

Alexander H Seeto,[1] Bo Abrahamsen,[2,3,4] ![ORCID] Peter R Ebeling,[5,6†] ![ORCID] and Alexander J Rodríguez[2,5,7†] ![ORCID]

[1]School of Medicine, Griffith University, Gold Coast, Australia
[2]OPEN-Odense Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
[3]Musculoskeletal Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
[4]Department of Medicine, HolbaekHospital, Holbaek, Denmark
[5]Bone and Muscle Health Research Group, Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Monash Medical Centre, Clayton, Australia
[6]Australian Institute for Musculoskeletal Science, St Albans, Australia
[7]Disorders of Mineralisation Research Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia

ABSTRACT

The cardiovascular safety of denosumab has not yet been evaluated in a systematic review. This systematic review and meta-analysis sought to quantify the number of randomized controlled trials (RCTs) of denosumab (against comparators) reporting cardiovascular adverse events (CAEs) and examine the balance of CAEs between treatment arms. MEDLINE, Embase, and clinicaltrials.gov were searched from inception to October 26, 2019, for RCTs of denosumab versus comparators for any indication. Included trials were randomized, enrolled ≥100 participants, and reported bone-related outcomes. Primary outcome for analysis was all CAEs, a composite endpoint representing summation of all CAEs as reported by included trials. Secondary outcomes included major adverse cardiovascular events (MACE). Data were pooled using a fixed effects model to determine relative risk (RR) and 95% confidence interval (95% CI). Risk of bias was assessed using the Cochrane risk-of-bias tool. Of 554 records screened, 49 were included, while 36 reported CAEs. Twenty-seven included trials (12 eligible for meta-analysis) were conducted in 13,202 postmenopausal women. Compared with bisphosphonates, there was a 46% (95% CI 1.05 to 2.02) increase in CAEs (85/2136 events in denosumab-treated versus 58/2131 events in bisphosphonate-treated; seven trials). There was a similar imbalance in a five-point (stroke, myocardial infarction, cardiovascular death, heart failure, atrial fibrillation) MACE endpoint (28/2053 versus 12/2050; RR = 2.33 [1.19 to 4.56]). Compared with placebo-treated women, there was no imbalance in total CAEs (439/4725 events in denosumab versus 399/4467 in placebo; RR = 0.79 [0.41 to 1.52]; seven trials). No imbalance in total AEs (versus bisphosphonates: 0.98 [0.92 to 1.04]; versus placebo: 0.99 [0.98 to 1.01]) occurred. Other indications showed no statistically significant results. The excess CAEs in postmenopausal women treated with denosumab compared with bisphosphonates, but not placebo, indirectly supports claims that bisphosphonates may suppress CAEs. Future trials should use standardized CAE reporting to better describe cardiovascular effects of bone active medications. (PROSPERO: CRD42019135414.) © 2020 American Society for Bone and Mineral Research (ASBMR).

KEY WORDS: ANTIRESORPTIVES; CANCER; CLINICAL TRIALS; MENOPAUSE; OSTEOPOROSIS

Introduction

In aging populations, osteoporosis is a growing public health concern. Osteoporosis does not exist in isolation but often coexists with other age-related diseases, particularly cardiovascular diseases.[1] Literature suggests that cardiovascular diseases (CVD) contribute a major proportion to mortality after a fragility fracture.[2] Thus, greater appreciation of the need for CVD management alongside fracture risk is warranted across clinical specialties.

Lessons from previous studies involving bisphosphonates (BPs) have suggested that BPs may suppress cardiovascular

adverse events (CAEs).[3–5] Thus, in BP-controlled randomized controlled trials (RCTs), any increase in CAEs could actually represent an artificial elevation. Accordingly, a new agent for osteoporosis, the anti-sclerostin antibody romosozumab, has shown skeletal benefit but an increased risk of CAEs when compared with BPs but not with placebo.[6–8] This served as the scientific motivation to reevaluate the cardiovascular safety profile of denosumab.

Denosumab is a human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which exerts potent antiresorptive effects.[9] Studies have reported that denosumab exhibited a similar safety profile compared with BPs.[10] However, given the suspected cardio-protective benefit of BPs, no study has specifically examined the distribution of CAEs in denosumab-treated patients versus BP treatments or indeed for other treatments, including placebo.

Two previous meta-analyses have reported on the cardiovascular safety of denosumab.[11,12] However, these studies exclusively evaluated trials in postmenopausal women and findings were limited. One review only included placebo-controlled trials and the other pooled active and placebo-controlled trials, as well as mixed population groups. Both previous reviews failed to include the trial by McClung and colleagues, the seminal article in the clinical development of denosumab.[13] Furthermore, denosumab has a number of indications for use and the cardiovascular effects are uncertain in other groups. Our systematic review evaluated cardiovascular safety in all populations and thus provides a more comprehensive overview of the prescribing landscape. Furthermore, these previous meta-analyses did not evaluate the quality of CAE reporting in RCTs. Our review reports the overall quality of CAE reporting in RCTs and aids in the design and CAE reporting of future trials. Thus, the objectives of this systematic review were to: (i) evaluate the overall quality of CAE reporting and (ii) assess the balance of CAEs across all indications for which denosumab is prescribed.

Materials and Methods

Data sources and searches

We searched MEDLINE, EMBASE, and clinicaltrials.gov from inception to October 26, 2019, with no language restrictions for eligible records. Records were identified using the following title and abstract terms: "denosumab" AND ("fracture" OR "bone density" OR "bone mineral density" OR "skeletal-related events") AND "random*". Records were stored using a citation manager and duplicates were removed. We screened all titles and abstracts and following screening; full texts were examined to evaluate eligibility. We also manually screened reference lists of eligible texts and online related article lists to identify potentially relevant manuscripts.

Study selection

We conducted this systematic review and meta-analysis in accordance with the PRISMA statement,[14] and it is registered with PROSPERO (CRD42019135414). We aimed to determine: (i) the number of studies that specifically report CAEs; and (ii) determine the balance of CAEs across the indications for which denosumab is prescribed. Studies were eligible if the trial was randomized, used denosumab, randomized at least 100 participants, and reported bone-related outcomes, including bone mineral density (BMD), incident fractures (at any site), or

skeletal-related events (SREs). Specific exclusion criteria included non-randomized studies, systematic reviews, reviews, conference abstracts, letters, case reports, and animal or cell-based studies.

Data extraction and quality assessment

Data were tabulated by a single reviewer (AHS) using a data extraction template and was checked for accuracy by another reviewer (AJR). We sought the total enrolled patients; comparator; known fractures at baseline; follow-up length; inclusion and exclusion criteria, if study reported CAEs; age, sex, baseline BMD of participants at baseline; and dosage, frequency, and route of administration of intervention. A weighted average of age and baseline vertebral and nonvertebral BMD were calculated for meta-regression.

Adverse event (AE) data were collected using a separate data extraction template. We tabulated any and all AEs as well as all specific CAEs listed in each study. Where available, additional data on publications were sought on clinicaltrials.gov. Given the heterogeneity in reported CAEs, we created a composite outcome, which was a summation of all reported specific CAEs. Each CAE was assigned equal weight since reporting of CAEs was ultimately event driven. For studies with available data, we also created a major adverse cardiovascular event (MACE) endpoint. Our three-point MACE (MACE3) comprised myocardial infarction (MI), stroke, and CVD death; four-point MACE (MACE4) comprised MACE3 and heart-failure (HF), and five-point MACE (MACE5) comprised MACE4 and atrial fibrillation.

We used the Cochrane Collaboration risk-of-bias tool for randomized trials to assess risk of bias.[15] This tool evaluates bias across seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (eg, representativeness). A judgment of low, unclear, or high risk of bias was made for each domain. An overall risk of bias per study was evaluated based on the following criteria: low—all domains low; low/unclear—all domains low except for one that was unclear; unclear—greater or equal to two unclear domains; high—any domain was high. Two independent reviewers (AHS and AJR) performed the assessment. For studies where there was disagreement between the reviewers regarding the overall risk of bias, discrepancies were resolved by a consensus meeting.

Data synthesis and analysis

Studies were eligible for meta-analysis if they initially satisfied the inclusion–exclusion criteria, reported CAE data, were not extensions of clinical trials, and there were at least two studies with relevant data per indication or comparator. Analysis was performed separately by indication and by comparator (BP or placebo). For example, within the postmenopausal women population, denosumab was compared with bisphosphonate and placebo in two separate analyses. For all studies that reported CAEs, we additionally analyzed the balance of all AEs as a measure of internal validity. We used all AEs as opposed to serious AEs because of the heterogeneous classification of serious AEs between trials. Data were synthesized using a Mantel–Haenszel fixed effects model reporting relative risk (RR) and 95% confidence interval (95% CI). Where heterogeneity was substantial ($I^2 > 50\%$), a random effects model was used. All data were computed using Stata v14.2 using the *metan* package

(College Station, TX, USA). Sensitivity analysis was performed through a leave-one-out analysis for any statistically significant result. We identified age, prevalence of smokers, body mass index, and vertebral and nonvertebral BMD as potential clinical modifiers for cardiovascular risk. Thus, we investigated these potential sources of heterogeneity by using meta-regression. We also investigated study size as a potential source of methodological heterogeneity. Publication bias was assessed by visual inspection of a funnel plot.

Results

Literature search

The literature search yielded 554 results. Forty-nine duplicates were removed, leaving 505 records for title and abstract screening where 459 records were excluded primarily due to having a population <100 ($n = 34$); no randomization ($n = 84$); conference abstracts ($n = 92$); systematic reviews ($n = 77$); or did not investigate bone-related outcomes ($n = 63$). Forty-six full-text articles were assessed for eligibility, of which six were removed primarily for having a population size <100, which were not reported in the abstract ($n = 3$). Additional hand searching found another nine articles. Overall, 49 studies were included in the qualitative synthesis (Fig. 1).

Included studies

Of the articles included in the qualitative synthesis, 46 articles had published results and three unpublished trials had relevant data available on clinicaltrials.gov. Studies were conducted across numerous indications: postmenopausal women with osteoporosis or low BMD ($n = 27$), bone metastasis ($n = 8$), multiple myeloma ($n = 1$), prostate cancer ($n = 4$), breast cancer ($n = 2$), elderly men and women ($n = 3$), patients with glucocorticoid-induced osteoporosis ($n = 1$), patients with rheumatoid arthritis ($n = 2$), and men with low BMD ($n = 1$). Twenty-six studies were conducted in the United States; five in Canada and Japan; two each in China, France, Italy, and Australia; and one each in Austria, India, Belgium, England, and Korea. All trials


Fig 1. Study selection flow diagram.

Table 1. Included Study Details

Study (year), country	Total enrolled (n)	Comparator	Follow-up	Known fractures at baseline[a]	Primary endpoints	Efficacy	CAE reporting
Neoplastic bone disease							
Fizazi et al. (2009), France[16]	111	Any bisphosphonate	Variable	Unclear	Progression of bone metastasis	↓42% IR	No
Fizazi et al. (2011), France[19]	1904	Zolendronate	40.5	Unclear	Time to first on-study SRE	↓18%	Yes
Henry et al. (2011), United States[20]	1776	Zoledronate	24	Unclear	Time to first on-study SRE	↓16%	Yes
Henry et al. (2014) United States[21]	1597	Zoledronate	6.7	Unclear	Time to first on-study SRE (ad hoc analysis of [20])	↓19%	No
Lipton (2007), United States[22]	255	Any bisphosphonate	14	Unclear	Progression of bone metastasis	↑8% IR	No
NCT01920568 (2013), United States[23]	485	Zoledronate	12.25	Unclear	Progression of bone metastasis	Mean Difference = 6	Yes
Raje et al. (2018), United States[24]	1718	Zoledronate	50	Unclear	Time to first on-study SRE	↓2%	Yes
Smith et al. (2015), United States[25]	1901	Zoledronate	36	Unclear	SSEs (study extension of [19])	↓22%	Yes
Stopeck et al. (2010), United States[26]	2046	Zoledronate	34	Unclear	Time to first on-study SRE	↓18%	Yes
Postmenopausal women							
FREEDOM Trial[9]							
Cummings et al. (2009), United States[9]	7808	Placebo	36	Yes	New vertebral fracture (primary trial)	↓68%	Yes
Adami et al. (2012), Canada[27]	667	Placebo	36	Yes	Delayed fracture healing (extension of [9])	→	Yes
Bone et al. (2017), United States[18]	4550	Placebo	120	Yes	Safety monitoring—AE incidence (extension of [9])	→	No
Boonen et al. (2011), Belgium[28]	7762	Placebo	36	Yes	Fracture incidence for those at fracture risk (post hoc analysis of [9])	↓9.1%IR	No
Eastell et al. (2011), England[29]	160	Placebo	36	Yes	BTMs (extension of [9])	→	No
Samelson et al. (2014), United States[30]	1625	Placebo	36	Yes	Progression of aortic calcification, incidence of CAEs (extension of [9])	=, ↓2%IR	Yes
McClung et al. (2006) Trial[13]							
McClung et al. (2006), United States[13]	93	Placebo	12	Yes	% change in lumbar spine BMD at month 12 (primary trial)	↑3.0–6.7% vs. ↓0.8	Yes
McClung et al. (2006), United States[13]	94	Alendronate	12	Yes	% change in lumbar spine BMD at month 12 (primary trial)	3.0–6.7% vs. ↑4.6%	Yes
Lewiecki et al. (2007), United States[31]	365	Placebo	24	Yes		↑, ↓	Yes

(Continues)

Table 1. Continued

Study (year), country	Total enrolled (n)	Comparator	Follow-up	Known fractures at baseline[a]	Primary endpoints	Efficacy	CAE reporting
Lewiecki et al. (2007), United States[31]	366	Alendronate	24	Yes	BMD at lumbar spine, total hip, and one-third radius, BTM (extension of [13])	↑, ↓	Yes
Miller et al. (2008), United States[32]	365	Placebo	48	Yes	BMD at lumbar spine and total hip, BTM (2-year denosumab extension of [13])	↑, ↓	Yes
Miller et al. (2008), United States[32]	366	Alendronate	48	Yes	BMD at lumbar spine and total hip, BTM (2-year denosumab extension of [13])	↑, ↓	Yes
Miller et al. (2011), United States[33]	200	N/A	72	Yes	BMD at lumbar spine, total hip, femoral neck, and one-third radius, BTM (4-year denosumab extension of [13])	↑, ↓	Yes
McClung et al. (2013), United States[34]	200	N/a	48	Yes	BMD at lumbar spine and total hip, BTM (8-year denosumab extension of [13])	↑, ↓	Yes
Other trials							
Bone et al. (2008), United States[35]	322	Placebo	24	No	% change lumbar spine BMD at 24 months (primary trial)	↑7.1%	Yes
Bone et al. (2011), United States[36]	256	Placebo	24	No	% change in BMD, % change BTMs (off-treatment extension of [35])	↑6.4%, ↓63%	Yes
Brown et al. (2009), Canada[37]	1189	Alendronate	12	Yes	% change in the total hip BMD at month 12	MD = ↑0.9%	Yes
Brown et al. (2014), Canada[38]	1703	Any bisphosphonate	12	Yes	% changes from baseline in BMD, % change serum C-telopeptide of type I collagen (sCTX-1) (combined post hoc analysis of [39,40])	↑1.4%, ↓23%	Yes
Kendler et al. (2010), Canada[41]	504	Alendronate	12	Yes	% change in the total hip BMD at month 12	↑0.85%	Yes
Koh et al. (2016), Korea[42]	135	Placebo	12	Yes	% change in the lumbar spine BMD at month 6	↑3.2%	No
Miller et al. (2016), United States[43]	643	Zoledronate	12	Yes	% change in lumbar spine BMD at month 12	↑2.1%	Yes
Nakamura et al. (2012), Japan[44]	108	Placebo	12	Yes	% change in lumbar spine BMD at month 12 (14 mg denosumab)	↑5.71%	Yes

(Continues)

Table 1. Continued

Study (year), country	Total enrolled (n)	Comparator	Follow-up	Known fractures at baseline[a]	Primary endpoints	Efficacy	CAE reporting
Nakamura et al. (2012), Japan[44]	109	Placebo	12	Yes	% change in lumbar spine BMD at month 12 (60 mg denosumab)	↑6.73%	Yes
Nakamura et al. (2012), Japan[44]	105	Placebo	12	Yes	% change in lumbar spine BMD at month 12 (100 mg denosumab)	↑7.45%	Yes
NCT01495000 (2012), India[17]	250	Placebo	6	Unclear	% change in lumbar spine BMD at month 6	↑3.06%	Yes
NCT02014467 (2014), China[45]	484	Placebo	12	Yes	% change in lumbar spine BMD at month 12	↑4.43%	Yes
Recknor et al. (2013), United States[39]	833	Ibandronate	12	Yes	% change in total hip BMD at month 12	↑1.2%	Yes
Roux et al. (2014), France[40]	870	Risendronate	12	Yes	% change in total hip BMD at month 12	↑1.5%	Yes
Seeman et al. (2010), Australia[46]	165	Placebo	12	No	Cortical thickness of radius (primary trial)	↑4.2%	Yes
Seeman et al. (2010), Australia[46]	165	Alendronate	12	No	Cortical thickness of radius (primary trial)	↑1%	Yes
Zebaze et al. (2014), Australia[47]	92	Alendronate	12	No	% Porosity (extension of [46])	↓0.78%	No
Prostate cancer							
Doria et al. (2017), Italy[48]	234	Alendronate	24	Yes	% change in lumbar spine BMD at month 24,	↑6.7%	No
Egerdie 2012, Canada[49]	1468	Placebo	36	Yes	% change in lumbar spine BMD at month 36 (responder analysis of [50])	↑7.9%	No
Smith et al. (2009), United States[50]	1468	Placebo	36	Yes	% change in lumbar spine BMD at month 24	↑6.6%	Yes
Smith et al. (2012), United States[51]	1432	Placebo	36	Unclear	Bone-metastasis-free survival (months)	↑4.2 months	Yes
Breast cancer							
Ellis et al. (2008), United States[52]	252	Placebo	12	No	% change in lumbar spine BMD at month 12	↑5.5%	Yes
Gnant et al. (2015), Austria[53]	3425	Placebo	72	Unclear	Time from randomization until the date of the radiograph confirming the first clinical fracture	↓50%	Yes
Men and Women							
Nakamura et al. (2014), Japan[54]	952	Placebo	24	Yes	24-month incidence of new or worsening vertebral fracture	↓6.7% IR	Yes
Nakamura et al. (2014), Japan[54]	714	Alendronate	24	Yes	24-month incidence of new or worsening vertebral fracture	↓5% IR	Yes

(Continues)

Table 1. Continued

Study (year), country	Total enrolled (n)	Comparator	Follow-up	Known fractures at baseline[a]	Primary endpoints	Efficacy	CAE reporting
Niimi et al. (2018), Japan[55]	200	Alendronate	24	Yes	% change in lumbar spine BMD at month 12, % change in femoral neck BMD at month 12	↑3%, ↑0.7%	No
Niimi et al. (2018), Japan[55]	200	Minodoronate	24	Yes	% change in lumbar spine BMD at month 12, % change in femoral neck BMD at month 12	↑3.8%, ↑1.2%	No
Sugimoto et al. (2015), Japan[56]	1262	Placebo	24	Yes	36-month incidence of new or worsening vertebral fracture (1-year open-label extension of[54])	↓74%	Yes
GIOP Saag et al. (2018), United States[57]	795	Risendronate	N/A	Yes	% change in lumbar spine BMD at month 12 in glucocorticoid-continuing patients, % change in lumbar spine BMD at month 12 in glucocorticoid-initiating patients	↑1.1%, ↑3%	Yes
Rheumatoid arthritis Cohen et al. (2008), United States[58]	146	Placebo	12	Unclear	Mean change in MRI erosion score from baseline to 6 months	↓1.62	Yes
Takeuchi et al. (2016), Japan[59]	340	Placebo	12	Unclear	Change in the modified Sharp erosion score from baseline to 12 months	↓0.99	Yes
Men Orwoll et al. (2012), United States[60]	242	Placebo	24	Yes	% change in lumbar spine BMD at month 12	↑4.8%	Yes

CAE = cardiovascular adverse event; IR = incidence rate; SRE = skeletal-related event; SSE = symptomtic skeletal event; BTM = bone turnover marker; BMD = bone mineral density; GIOP = glucocorticoid-induced osteoporosis.

[a]Known fractures at baseline indicates that a trial permitted the inclusion of patients with any form of fracture.

Table 2. Risk of Bias Assessment

Indication	Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias	Consensus
Postmenopausal women	Adami et al. (2012)[27]	?/?	–/–	?/–	–/?	–/–	–/–	–/?	Unclear
	Bone et al. (2008)[35]	?/?	?/–	–/?	?/?	–/+	–/?	?/–	Unclear
	Bone et al. (2011)[36]	?/?	?/–	–/–	?/?	–/–	–/?	–/+	Unclear
	Bone et al. (2017)[18]	?/?	–/–	?/+	–/?	–/?	–/?	+/–	High
	Boonen et al. (2011)[28]	?/?	–/–	?/–	–/?	?/?	?/–	–/?	Unclear
	Brown et al. (2009)[37]	–/–	?/–	–/?	?/?	–/–	–/–	+/+	High
	Brown et al. (2014)[38]	?/?	?/?	+/+	?/?	?/–	–/–	+/+	High
	Cummings et al. (2009)[9]	?/?	–/–	?/–	–/?	–/–	–/+	–/+	High
	Eastell et al. (2011)[29]	?/?	–/–	?/–	–/?	?/–	?/+	+/+	High
	Kendler et al. (2010)[41]	–/–	?/–	–/–	–/?	–/–	–/–	?/?	Unclear
	Koh et al. (2016)[42]	?/?	?/?	–/?	?/?	–/–	–/–	+/+	High
	Lewiecki et al. (2007)[31]	–/?	?/–	+/+	?/?	–/+	–/–	+/+	High
	McClung et al. (2006)[13]	–/?	?/–	+/+	?/?	–/–	?/–	+/+	High
	McClung et al. (2013)[34]	–/?	?/–	+/+	?/?	?/?	?/+	–/?	High
	Miller et al. (2008)[32]	–/?	?/?	+/+	?/?	–/+	–/?	+/?	High
	Miller et al. (2011)[33]	–/?	?/?	+/+	?/?	?/?	?/?	+/?	High
	Miller et al. (2016)[43]	?/?	?/?	–/–	–/?	–/–	–/–	–/–	Unclear
	Nakamura et al. (2012)[44]	?/?	?/?	–/–	?/–	?/–	–/–	–/–	Unclear
	Recknor et al. (2013)[39]	–/–	?/–	+/–	+/?	+/–	?/–	–/–	High

(Continues)

Table 2. Continued

Indication	Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias	Consensus
	Roux et al. (2014) [40]	?/?	?/?	+/+	+/?	?/–	?/–	–/–	High
	Samelson et al. (2014) [30]	?/?	–/–	?/–	–/?	?/?	+/+	–/?	High
	Seeman et al. (2010) [46]	–/–	–/–	–/–	–/?	–/+	–/–	+/+	High
	Zebaze et al. (2014) [47]	–/–	?/–	–/–	?/?	?/–	?/?	–/?	Unclear
Neoplastic bone disease	Fizazi et al. (2009) [16]	?/?	?/–	+/+	+/+	–/?	–/?	–/–	High
	Fizazi et al. (2011) [19]	–/–	–/–	–/–	–/–	–/?	–/+	–/+	High
	Henry et al. (2011) [20]	–/–	–/–	–/–	–/–	–/?	–/+	–/–	High
	Henry et al. (2014) [21]	?/?	–/?	–/–	–/?	–/?	–/+	–/?	High
	Lipton (2007) [22]	?/?	?/+	+/+	?/?	?/–	?/+	–/–	High
	Raje et al. (2018) [24]	–/–	–/–	–/–	–/?	–/+	–/?	+/?	High
	Smith et al. (2015) [25]	–/?	–/–	–/–	–/?	?/?	?/?	–/?	Unclear
	Stopeck et al. (2010) [26]	?/–	?/?	–/?	–/?	–/?	–/+	–/?	High
Prostate cancer	Doria et al. (2016) [48]	?/?	?/?	–/–	?/?	?/?	–/+	?/?	Unclear
	Egerdie et al. (2012) [49]	?/?	–/–	–/–	?/?	?/?	?/+	+/?	High
	Smith et al. (2009) [50]	?/–	?/?	–/?	–/?	?/?	?/–	+/?	High
	Smith et al. (2012) [51]	–/–	–/–	–/?	–/?	–/–	–/–	+/+	High
Breast cancer	Ellis et al. (2008) [52]	?/?	–/?	–/–	?/?	–/?	–/+	+/?	High
	Gnant et al. (2015) [53]	–/–	–/–	–/–	–/–	?/?	–/–	+/+	High
Glucocorticoid Users	Saag et al. (2018) [57]	–/–	–/–	–/+	?/–	–/+	–/?	–/+	High

(Continues)

Table 2. Continued

Indication	Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias	Consensus
Men and postMenopausal women	Nakamura et al. (2014)[54]	?/?	?/?	–/+	–/?	–/?	–/–	–/+	High
	Niimi et al. (2018)[55]	–/–	?/?	+/?	–/?	–/–	?/?	–/–	High
	Sugimoto et al. (2014)[56]	?/?	?/?	–/+	?/?	?/?	?/+	–/–	High
Rheumatoid arthritis	Cohen et al. (2008)[58]	?/–	?/?	–/?	–/–	–/–	–/?	+/?	High
	Takeuchi et al. (2016)[59]	–/–	–/–	–/–	–/–	–/?	–/–	+/?	High
Healthy older men	Orwoll et al. (2012)[60]	–/–	–/?	–/–	–/–	–/–	–/–	+/–	High

supplemented patients with calcium and/or vitamin D. Sixteen of the 46 studies were extensions of primary trials. We focused on primary trials for data analysis because many extensions crossed over patient treatment arms or were open-label extensions. Once unblinding or crossover takes place, we cannot attribute particular CAEs exclusively to denosumab or other medications. The smallest trial enrolled 111 patients,[16] and the largest trial enrolled 7808 patients.[9] Follow-up time varied between a minimum of 6 months[17] and a maximum of 120 months.[18] Nineteen studies enrolled patients who had previous fractures at baseline, four studies excluded patients with fractures at baseline, and 23 were unclear. For dose finding studies, we preferentially chose to report on the dose used most widely in clinical practice for the most relevant data (Table 1).

Literature quality

Most studies were rated as high ($n = 33$) or unclear ($n = 11$), whereas one was rated low/unclear (Table 2) quality. Most studies reported randomization methods, allocation concealment, and blinding poorly. In studies in which postmenopausal women were enrolled, higher nominal risks of bias were often related to trial sponsors participating in study design, data collection, and manuscript writing. In trials enrolling patients with bone neoplasms, high risk of bias was predominantly related to high dropout rate attributed to death or withdrawal of consent.

Adverse events

Forty-six trials (93.9%) reported data on any AEs.[9,13,16–46,49–54,56–60] Of these, only 36 reported CAEs. Twenty-six studies had data available to form a composite cardiovascular disease endpoint.[9,13,17,19,20,23,24,26,35,37,39–41,43–46,50–54,57,58,60] Eleven studies already reported "any cardiovascular" AEs,[9,24,30,36,38,39,43–45,53,54] whereas six reported "any vascular" AEs.[24,30,38,43,44,53] The most commonly reported specific CAEs were myocardial infarction ($n = 17$), hypertension ($n = 16$), atrial fibrillation ($n = 16$), coronary artery disease ($n = 13$), and cerebrovascular accident ($n = 13$) (Supplemental Table S1). There were 79 specific CAEs that were reported once; for example, "peripheral vascular disease" was reported in only one trial.[9] All studies did not report an imbalance of overall AEs between denosumab and control groups.[9,13,16–46,49–54,56,58–60]

Meta-analysis

Twenty-six trials, including 30,308 participants, were eligible for meta-analysis, including 12 placebo-controlled trials, 11 BP-controlled trials, and three trials with placebo and BP-controlled arms.

Postmenopausal women with osteoporosis or low BMD

In postmenopausal women, there were 11 BP-controlled trials (alendronate $n = 7$, risedronate $n = 1$, ibandronate $n = 1$, zoledronic acid $n = 1$, combination $n = 1$).[13,31,32,37–41,43,46,47] Nine of these trials were only compared with bisphosphonates, whereas two had BP and placebo comparator arms. Seven trials had CAE data for meta-analysis whereby there were 85 CAEs in 2136 women randomized to denosumab compared with 58 CAEs in 2131 women randomized to any bisphosphonate (RR = 1.46 [95% CI 1.05 to 2.02]) (Fig. 2). The lower boundary for this effect estimate (1.05) may not represent a clinically important effect. Thus, in a post hoc exploratory analysis, we calculated up to what

Study ID		RR (95% CI)	Events, Treatment	Events, Control	% Weight
McClung_2006		0.70 (0.24, 2.04)	5/47	7/46	12.17
Brown_2009		0.73 (0.30, 1.80)	8/593	11/596	18.87
Seeman_2009		0.98 (0.29, 3.24)	5/83	5/81	8.71
Roux_2014		1.59 (0.88, 2.87)	27/429	17/429	29.24
Miller_2016		1.70 (0.79, 3.66)	17/320	10/320	17.20
Kendler_2010		2.30 (0.60, 8.78)	7/253	3/249	5.20
Recknor_2013		3.19 (1.18, 8.63)	16/411	5/410	8.61
Overall (I-squared = 20.4%, p = 0.274)		1.46 (1.05, 2.02)	85/2136	58/2131	100.00

Lower risk with Denosumab use · Lower risk with BP use

Fig 2. Forest plot of the balance of cardiovascular events in denosumab-treated postmenopausal women compared with bisphosphonates.

level of confidence we can obtain a minimum clinically important effect size of 15%. We determined that this minimum clinically important effect was found at the 85% level (RR = 1.46 [85% CI 1.15 to 1.85]). Therefore, although we found an excess risk of 46%, we can only refute the 15% risk increase at a $p = 0.15$. Age (beta coefficient = 0.17, 95% CI −0.11 to 0.45), population size (beta coefficient = 0.00, 95% CI −0.00 to 0.00), previous fracture (beta coefficient = 1.01, 95% CI −2.07 to 3.47), baseline BMD (beta coefficient = −0.06, 95% CI −7.93 to 6.66), and baseline nonvertebral BMD (beta coefficient = −1.77, 95% CI −6.52 to 2.98) were adequately reported to enable meta-regression, for which no influence was noted. Funnel plot inspection indicated minimal risk of publication bias (Supplemental Fig. S1). A number needed to harm (NNH) analysis found that for every 79 (95% CI 35 to 714) patients treated with denosumab compared with BPs, there would be one excess CAE. All the trials that provided data for NNH were 12 months in length. Thus, if 1000 women were treated for 1 year, there would be an excess of 12.5 events (95% CI 1.4 to 27.8) in those receiving denosumab relative to those receiving BPs. Three-point and four-point MACE comparing denosumab to bisphosphonates in postmenopausal women showed nonstatistically significant increases (MACE3: 16/2053 versus 10/2050, RR = 1.57 (0.73 to 3.39); MACE4: 21/2053 versus 10/2050, RR = 2.04 (0.98 to 4.26). However, there was imbalance using a five-point MACE definition, which included atrial fibrillation (28/2053 versus 12/2050; RR = 2.33 [1.19 to 4.56]) (Table 4). There was no imbalance in total AEs in postmenopausal women (Supplemental Fig. S2).

Fifteen trials were placebo-controlled ($n = 13$ placebo only; $n = 2$ placebo and BPs).[9,13,17,18,27–32,34–36,42,44–47] Of which, seven had CAE data for analysis, which found 439 events in 4725 denosumab-treated women and 399 events in 4467

placebo-treated women RR (95% CI RR = 0.79 [0.41 to 1.52]) (Table 3). Regarding MACE outcomes, there were nonsignificant increases in MACE3, MACE4, and MACE5 (Table 4). There was no imbalance in total AEs in postmenopausal women (Table 3).

A leave-one-out sensitivity analysis was performed for both the composite CAE and five-point MACE analysis for the statistically significant results. Within the composite CAE analysis, individual removal of trials by Recknor and colleagues, Roux and colleagues, and Miller and colleagues led to a loss of statistical significance (Supplemental Table S2).[39,40,43] In the five-point MACE analysis, when the trial by Recknor and colleagues was removed, the result lost statistical significance (Supplemental Table S3).[39] Furthermore, to assess whether the background risk in individual studies was associated with its magnitude of relative risk for the overall effect estimate, we plotted the event rate in the BP arm (x axis) against overall effect estimate for the any CAE endpoint analysis (y axis) (Supplemental Fig. S3). Although an inverse trend was observed, linear regression for the line of best fit was not significant ($\beta = −10.8$ [−27.8 to 6.2]). Owing to the small number of trials, there was quite notable variance between studies, and the trials by Brown and colleagues and Recknor and colleagues were clear outliers.[37,39]

Neoplastic bone disease

We grouped together bone metastasis and multiple myeloma into the category of neoplastic bone disease because denosumab is indicated in both disease processes to prevent skeletal-related events due to increases in osteoclast-mediated bone resorption.[24,61] This category encompasses both primary and metastatic neoplasms of bone. Nine trials were BP-controlled (zoledronic acid $n = 7$, combination $n = 2$).[16,19–26]

Table 3. Relative Risk of CAEs in Denosumab-Treated Individuals Against Comparators

Versus	Indication	No. of studies	RR (95% CI)	Events		I²	Ref.
				Denosumab	Control		
CAE	Bisphosphonates						
	Postmenopausal women	7	1.46 (1.05, 2.02)	85/2136	58/2131	20.4%	(13, 37, 39–41, 43, 46)
	Neoplastic bone disease	5	1.01 (0.88, 1.15)	383/4017	380/3847	50.1%	(19, 20, 23, 24, 26)
	Men and postmenopausal women	1	1.65 (1.04, 2.62)	68/475	21/242	0.0%	(54)
	GIOP	1	1.73 (0.89, 3.36)	23/394	13/385	0.0%	(57)
	Placebo						
	Postmenopausal women[a,b]	7	0.79 (0.41, 1.52)	439/4725	399/4467	53.6%	(9, 13, 17, 35, 44–46)
	Prostate cancer	2	1.07 (0.91, 1.25)	262/1451	242/1430	0.0%	(50, 51)
	Breast cancer	2	0.87 (0.67, 1.12)	103/1838	117/1810	0.0%	(52, 53)
	Men and postmenopausal women	1	1.09 (0.79, 1.50)	68/475	63/481	0.0%	(54)
	Men with low BMD	1	1.67 (0.41, 6.82)	5/120	3/120	0.0%	(60)
	Rheumatoid arthritis[a]	2	0.66 (0.18, 2.47)	3/157	5/163	66.5%	(58, 59)
Any AE	Bisphosphonates						
	Postmenopausal women	7	0.98 (0.92, 1.04)	851/2206	870/2206	0.0%	(13, 37, 39–41, 43, 46)
	Neoplastic bone disease	5	1.00 (0.99, 1.01)	3596/4034	3584/3866	31.6%	(19, 20, 23, 24, 26)
	Men and postmenopausal women	1	1.00 (0.96, 1.03)	448/475	229/242	0.0%	(54)
	GIOP	1	1.05 (0.96, 1.15)	285/394	265/385	0.0%	(57)
	Placebo						
	Postmenopausal women	7	0.99 (0.98, 1.01)	3922/4661	3928/4404	0.0%	(9, 13, 17, 35, 44–46)
	Prostate cancer	2	1.01 (0.99, 1.03)	1314/1451	1282/1430	0.0%	(50, 51)
	Breast cancer	2	1.01 (0.98, 1.05)	1483/1838	1442/1810	0.0%	(52, 53)
	Men and postmenopausal women	1	1.02 (0.98, 1.05)	448/475	446/481	0.0%	(54)
	Men with low BMD	1	1.02 (0.87, 1.20)	86/120	84/120	0.0%	(60)
	Rheumatoid arthritis	2	0.94 (0.86, 1.03)	129/156	140/159	0.0%	(58, 59)

CAE = cardiovascular adverse event; RR = relative risk; CI= confidence interval; GIOP = glucocorticoid-induced osteoporosis; BMD = bone mineral density.
[a]Random effects model was used when there was substantial heterogeneity (I² > 50).
[b]Fixed effects model: RR = 1.09 (0.95, 1.23).

Table 4. Relative Risk of CAEs in Denosumab Treated Postmenopausal Women Versus Bisphosphonates or Placebo

Indication		Number of studies	RR (95% CI)	Events		I^2	Ref.
				Denosumab	Control		
Bisphosphonates	CAE composite	7	1.46 (1.05, 2.02)	85/2136	58/2131	20.4%	(13, 37, 39–41, 43, 46)
	3-point MACE: MI, stroke, CVD death	6	1.57 (0.73, 3.39)	16/2053	10/2050	0.0%	(13, 37, 39–41, 43)
	4-point MACE: MI, stroke, CVD death, HF	6	2.04 (0.98, 4.26)	21/2053	10/2050	0.0%	(13, 37, 39–41, 43)
	5-point MACE: MI, stroke, CVD death, HF, atrial fibrillation	6	2.33 (1.19, 4.56)	28/2053	12/2050	0.0%	(13, 37, 39–41, 43)
Placebo	CAE composite[a]	7	0.79 (0.41, 1.52)	439/4725	399/4467	53.6%	(9, 13, 17, 35, 44–46)
	3-point MACE: MI, stroke, CVD death	3	1.19 (0.90, 1.59)	101/4300	83/4039	0.0%	(9, 13, 45)
	4-point MACE: MI, stroke, CVD death, HF	3	1.08 (0.84, 1.38)	128/4300	117/4039	0.0%	(9, 13, 45)
	5-point MACE: MI, stroke, CVD death, HF, atrial fibrillation	3	1.08 (0.87, 1.34)	164/4300	150/4039	0.0%	(9, 13, 45)

CAE = cardiovascular adverse event; RR = relative risk; CI= confidence interval; MACE = major adverse cardiac event; MI = myocardial infarction; CVD = cardiovascular disease; HF = heart failure.MACE outcomes are composed of MI, stroke, CVD death, HF, and atrial fibrillation. MI outcomes consisted of acute coronary syndrome, acute myocardial infarction, coronary artery disease, and myocardial infarction. Stroke consisted of cerebrovascular accident, cerebral ischemia, hemorrhagic stroke, and ischemic stroke. HF consisted of cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive, and heart failure. CVD death and atrial fibrillation outcomes were composed of CVD death and atrial fibrillation, respectively.
[a]Random effects model was used when there was substantial heterogeneity ($I^2 > 50$). Fixed effects model: RR = 1.09 (0.95, 1.23).

Five of these trials had CAE data for meta-analysis and found a nonsignificant increase of CAEs in denosumab-treated patients versus bisphosphonates (Table 3). Three-, four-, and five-point MACE yielded nonsignificant increases of CAEs in denosumab-treated patients versus bisphosphonates. There was no imbalance in overall AEs.

Prostate and breast cancer

In the prostate cancer indication, three studies were placebo-controlled[49–51] and one study was alendronate-controlled.[48] There were two placebo-controlled trials with CAE data, which showed a nonsignificant increase in CAEs in denosumab-treated patients (Table 3). There was no imbalance of overall AEs. The alendronate-controlled trial did not report cardiovascular safety data, nor were any available through clinicaltrials.gov. Two placebo-controlled studies enrolled patients with breast cancer.[52,53] These trials found a nonsignificant decrease in CAEs in denosumab-treated patients versus placebo.[53] There was no imbalance of overall AEs between treatment arms (Table 3). In both the prostate and breast cancer populations, there were insufficient data to construct MACE outcomes.

Men and postmenopausal women with low BMD

Three trials enrolled both men and postmenopausal women.[54–56] One trial enrolled postmenopausal women and men older than 50 years, comparing denosumab with two control treatments—placebo or open-label alendronate.[54] The author was contacted to provide separate data for men and women to enable these data to be included in the main postmenopausal women analysis above, but no response was received. When compared with open-label alendronate, there was a statistically significant increase of CAEs in the denosumab arm (Table 3). However, there was no imbalance in overall AEs. When compared with placebo, there was a nonsignificant increase in CAEs in the denosumab arm. There was balance of overall AEs between placebo and denosumab. There were insufficient data to construct MACE outcomes.

An additional trial was a 1 year open-label extension phase of the previous trial in which all subjects received denosumab, which was ineligible for meta-analysis.[56] Another trial enrolled men and postmenopausal women comparing denosumab with alendronate or minodoronate.[55] There were no AE data available for analysis.

Other indications

One trial enrolled men with low BMD comparing denosumab with placebo. Nonsignificant increases in CAEs and overall AEs were observed in the denosumab arm (Table 3).[60] Two trials enrolled patients with rheumatoid arthritis[58,59] and compared denosumab with placebo. There was a nonsignificant reduction in CAEs and overall AEs in denosumab-treated patients. Another trial enrolled patients with glucocorticoid-induced osteoporosis and compared denosumab with risedronate.[57] There was a nonsignificant small increase in CAEs and overall AEs in

denosumab-treated patients. In each of these indications, there were insufficient data to construct MACE outcomes.

Discussion

In this systematic review of large randomized controlled trials of denosumab versus placebo or active comparators for any indication, we determined that there was an approximate 46% increase in CAEs in denosumab-treated compared with BP-treated postmenopausal women. Within the same indication, we analyzed a five-point MACE endpoint (comprising stroke, myocardial infarction [MI], heart failure [HF], cardiovascular death, and atrial fibrillation) and determined there was a doubling of risk for these events (Supplemental Fig. S2). Given that no such imbalance existed in placebo-controlled trials, we speculate that the imbalance in CAE rate in BP-controlled trials may reflect a relative suppression of events in the BP-treated women. Importantly, these results need to be interpreted with caution because CAEs were adverse event data that were not prespecified as trial outcomes. Furthermore, we note the potential for a study's background risk to drive the overall effect estimate; however, regression analysis for an association found this to be nonsignificant. There were either insufficient data or nonsignificant risk differences for other indications. Nevertheless, this highlights the need for careful CV risk management alongside fracture risk management among patients treated for osteoporosis. Given a new anabolic osteoporosis agent, romosozumab, has raised concerns over increased CV risk, this is an especially worthwhile consideration.[6,7] Our assessment of whether background risk was associated with relative risk is very pertinent to the trials that evaluated romosozumab, as some have commented that this phenomenon may have been responsible for the apparent chance imbalance in CAEs in BP-controlled romosozumab.[62] Thus, future trial designs may need to pay careful attention to the choice of comparator in order for outcomes to be both interpreted with confidence and relevant to real-world effects.

The increased CAEs in denosumab-treated postmenopausal women versus BPs align with previous studies suggesting, controversially, that there may be a protective benefit of BPs.[3–5] This hypothesis has gained credence since the reporting of romosozumab having increased serious CAEs compared with alendronate[6] but not against placebo.[8] There is no clear biological explanation for why an anti-sclerostin antibody would increase CV risk. Indeed, the natural history of patients with sclerosteosis demonstrate no excess CV risk.[63] Similarly, we observed increased risks in denosumab-treated postmenopausal women compared with BPs but not compared with placebo. Thus, we speculate that the increase in CAEs in denosumab is driven by a suppression of events in BP-treated individuals. This has been similarly observed in a recent RCT where the effects of zoledronate on cancer, cardiac events, and mortality in osteopenic women were evaluated.[4] Zoledronate was found to have a protective effect on cardiovascular endpoints. The authors of this study provided a brief overview of this cardio-protective phenomenon citing bisphosphonate's potential direct action on arteries via nitric oxide–mediated vasodilation, immunomodulatory effects in atherosclerosis, and influence on the mevalonate and cholesterol synthesis pathway. Indeed, different BPs such as alendronate, which was the most common BP comparator in our article, may have different CVD effects than zoledronate.

However, placebo-controlled alendronate and other oral bisphosphonate RCTs that report CAEs (other than atrial fibrillation) are lacking. We note a previous meta-analysis reporting oral alendronate was not associated with atrial fibrillation, but this was limited to Merck-sponsored trials and is thus not reflective of the literature.[64] Similarly, a safety analysis of pivotal oral ibandronate trials suggested no association with atrial fibrillation.[65–67] It is interesting to note that neither oral ibandronate trial reports CAEs in their adverse event analysis from the primary publications; it is provided in the pooled safety analysis.[67] Given this cardio-protective effect in our systematic review was only found in postmenopausal women (a population known to be at elevated increased CV risk), there may be some underlying explanation for the increased events related to the loss of the protective effect of estrogen and how this interacts with RANKL.[68]

Notably, our analysis is presented in the context of a recent meta-analysis that suggested that BP has no mortality benefit and thus prescription of BPs should only be made with skeletal outcomes in mind.[69] Further, Cummings and McCulloch recently offered an explanation for the CAE findings of the romosozumab trial and determined it was a chance finding.[62] This would appear at odds with the present study's findings, a study by Reid and colleagues, and a meta-analysis by Kranenburg and colleagues, which demonstrated a reduction in cardiovascular mortality and all-cause mortality.[4,5] In clinical practice, extra-skeletal considerations are important in our dialogue with patients when deciding how best to manage bone health and will also impact on the overall cost utility landscape. The specific effect of BPs on CV mortality could be masked by the outcomes contributing to the balance of overall mortality.

Other indications such as bone metastasis had different etiologies and rationales for prescribing denosumab, possibly explaining why nonsignificant findings were demonstrated in the present study. There were limited data assessing CV risk in the cancer setting (and indeed other indications), thus we are uncertain about the effects of denosumab on CV outcomes in these populations. Equally we are unable to comment if the supposed cardio-protective effect of BPs exists in these populations. Regardless of indication, the present study serves to highlight that these uncertainties are areas where further research is warranted as we cannot rule out potentially clinically important effects. This is especially the case given that of the 49 studies included for review, only 26 had data available to form composite CAEs. This review serves as a timely reminder for future osteoporosis studies to specifically report CV outcomes as part of their study design.

The studies included had some limitations. Risk of bias assessment showed that randomization methods were generally unclear, outcome reporting was poor, and sponsors played a large role in a number of studies through writing, data collection, and study design. Given that these studies were generally monitored by contractors outside the influence of the investigators and that the trials were of sufficient quality and integrity to be accepted by regulators such as the Food and Drug Administration and the European Medicines Agency, it may reflect more the conventions of reporting trials in the musculoskeletal area (where details are often not given of the randomization procedure as this is considered unlikely to be flawed in these circumstances) than any inherent issues with the randomization procedure or conduct of the study. Indeed, it can be argued that published studies are being held against Cochrane standards that had not yet been developed at the time when these articles were written.

Another limitation, which was more commonly found in the neoplastic bone disease trials, there was a large dropout rate. However, this phenomenon is often noted in studies enrolling these patients. Often, this was attributed to deaths during the intervention but also consent withdrawal contributed to the dropout rate. Large multicentered trials were also limited by heterogeneous AE reporting. By way of example, local hospital guidelines may dictate that a particular event may be classified under a particular ICD code, while at another center, it may be classified under a similar but distinct ICD code. In the trial by Raje and colleagues, three separate cardiac failure outcomes reported "cardiac failure," "cardiac failure congestive," and "cardiac failure chronic."[24] Although we can assume the broader classification of cardiac failure would capture these two subclassifications, we are uncertain as to whether all these events are independent. Similarly, most studies stated that overall AEs were either similar between groups or there were no AEs. The validity of such claims is limited since this overall balance of any AEs could be skewed by the selective reporting (or non-reporting) of certain specific AEs or the effect of specific AEs could be nullified by the overall balance between all AEs as described above. This further highlights the need to specifically assess CAEs, and we call for transparent reporting of such outcomes. Without such transparent reporting, any analysis of this literature may be misleading as evidenced by a recent meta-analysis by Lv and colleagues.[11] They observed a balance of CV events between denosumab and control groups. However, in doing this, they pooled bisphosphonates and placebo trials, as well as pooling trials of men, premenopausal women, and postmenopausal women in the same analysis. Our meta-analysis was performed separately by population and comparator, forming more homogenous groups to more comprehensively examine the effects of denosumab on cardiovascular safety. Furthermore, Lv and colleagues only included literature if the trial provided CAEs; however, as we have shown, not all trials report these data and often they are provided in online supplements or on their clinical trials registration page. We also note that McClung and colleagues' seminal trial in the clinical development of denosumab was not included.[13] Additionally, Lv and colleagues specifically excluded studies with zero CAEs. Again, this would provide an inaccurate view of the literature because as CAEs are known to occur in these patients, it is also important to consider when CAEs do not occur.

We also note another meta-analysis on this topic, but this too had severe limitations, rendering interpretation difficult.[12] Ferrieres and colleagues included extension trials in their overall analysis, which means that the AE data presented may not reflect the comparison between denosumab and other treatments. For example, Sugimoto and colleagues' study[56] was an extension trial where all participants received denosumab for 1 year (crossover) after a placebo-controlled initial 2-year period. Thus, we are uncertain whether the events reported are attributable to when participants received denosumab or placebo. Furthermore, our analysis has identified some studies not included in their analysis, such as the aforementioned seminal McClung and colleagues trial.[13] Other limitations were that there was a large degree of heterogeneity between trials due to different inclusion and exclusion criteria.

Our review also has some limitations. First, we used aggregate level data and subsequently statistical analyses were limited to conventional study level meta-analysis. Individual level data was not sought because of the magnitude of outcomes and it did not fit with our primary aim of determining how many trials reported CAEs in the public domain. Second, we excluded conference abstracts. Thus, there may have been unpublished data that could have potentially contributed to the review. Third, in dose finding studies, we chose the dose used most commonly in clinical practice to enable relevant comparisons. Fourth, we used a composite cardiovascular outcome, composed of all CAEs. We explored the validity of the composite CAE findings by analyzing event rates for MACEs, which provided consistent findings (when analyzing a MACE5 endpoint). We believe the signal of the composite CAE effect estimate is a true and clinically important result because the direction and magnitude of the MACE endpoints increased with further inclusion of outcomes and became statistically significant. This shows the composite CAE was internally validated. It is important to note that a composite outcome assumes the same weight of each individual outcome and a similar etiology of each. We attempted to explore the balance of specific CAEs between treatment groups, but 79 of these CAEs were only reported in one study. Since they were reported, they are potentially an AE of interest; therefore, if other studies do not report this AE, it is assumed it did not occur. Indeed, absence of an AE is also of interest. Although we appreciate the limitations of reporting all AEs in articles, such data should be readily accessible and consistent. Thus, a composite CAE was created to enable meta-analysis that has been applied in other similar studies.[70] We believe this strategy is robust because it resembles how each study reports on any AE, regardless of system and regardless of how many events occurred in any individual patient.

In conclusion, this systematic review identified an excess of CAEs in postmenopausal women with osteoporosis or low BMD treated with denosumab compared with bisphosphonates, but not placebo, indirectly supporting the claim that bisphosphates may supress CAEs. Overall, specific cardiovascular safety data were inconsistently reported and were limited for other indications. Future trials of anti-osteoporosis medications should use standardized CAE reporting to more clearly describe the cardiovascular effects of bone active medications.

Disclosures

Acknowledgments

AUTHOR CONTRIBUTIONS

Alexander Seeto: Methodology; writing-original draft; writing-review and editing. **Bo Abrahamsen:** Supervision; writing-review and editing. **Peter Ebeling:** Methodology; resources; supervision; writing-review and editing. **Alexander Rodriguez:** Methodology, data analysis, conceptualisation, supervision; writing-review and editing.

References

1. Samelson EJ, Kiel DP, Broe KE, et al. Metacarpal cortical area and risk of coronary heart disease: the Framingham study. Am J Epidemiol. 2004;159(6):589–95.

2. Browner WS, Seeley DG, Cummings SR, Vogt TM, for the Study of Osteoporotic Fractures Research Group. Non-trauma mortality in elderly women with low bone mineral density. Lancet. 1991;338 (8763):355–8.

3. Kang J-H, Keller JJ, Lin H-C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271–7.

4. Reid IR, Horne AM, Mihov B, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35(1):20–7.

5. Kranenburg G, Bartstra JW, Weijmans M, et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis. 2016;252:106–15.

6. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27.

7. Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis. J Clin Endocrinol Metabol. 2018;103 (9):3183–93.

8. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016; 375(16):1532–43.

9. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.

10. Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J Bone Miner Res. 2017;32(3):611–7.

11. Lv F, Cai X, Yang W, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis. Bone. 2020;130:115121.

12. Ferrieres L, Degboe Y, Laroche M, Constantin A, Ruyssen-Witrand A. No impact of anti-rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis. Arch Osteoporos. 2020;15(1):10.

13. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354(8):821–31.

14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

15. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.

16. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71.

17. GlaxoSmithKline. A study in Indian postmenopausal women with osteoporosis to evaluate the efficacy and safety of denosumab. 2012. Available at: https://ClinicalTrials.gov/show/NCT01495000.

18. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23.

19. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.

20. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9): 1125–32.

21. Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679–87.

22. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer. 2007;7(Suppl 1):S14–20.

23. GlaxoSmithKline, Amgen. A study to compare denosumab with zoledronic acid in subjects with bone metastases from solid tumors. 2013. Available at: https://ClinicalTrials.gov/show/NCT01920568.

24. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–81.

25. Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26(2):368–74.

26. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.

27. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94(23):2113–9.

28. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6): 1727–36.

29. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–7.

30. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450–7.

31. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12): 1832–41.

32. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2):222–9.

33. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96(2):394–402.

34. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1): 227–35.

35. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149–57.

36. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–80.

37. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–61.

38. Brown JP, Roux C, Ho PR, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int. 2014;25(7):1953–61.

39. Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291–9.

40. Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48–54.

41. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81.

42. Koh JM, Chung DJ, Chung YS, et al. Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension. Yonsei Med J. 2016;57(4):905–14.

43. Miller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163–70.

44. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012;23(3):1131–40.

45. GlaxoSmithKline. Denosumab China phase III study. 2014. Available at: https://ClinicalTrials.gov/show/NCT02014467.

46. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886–94.

47. Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173–9.

48. Doria C, Mosele GR, Solla F, Maestretti G, Balsano M, Scarpa RM. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. Minerva Urol Nefrol. 2017;69(3):271–7.

49. Egerdie RB, Saad F, Smith MR, et al. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2012;15(3):308–12.

50. Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.

51. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.

52. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–82.

53. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–43.

54. Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599–607.

55. Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A. Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial. JBMR Plus. 2018;2(5):289–94.

56. Sugimoto T, Matsumoto T, Hosoi T, et al. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int. 2015;26(2):765–74.

57. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–54.

58. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299–309.

59. Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoid arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75(6):983–90.

60. Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161–9.

61. Haslbauer F, Petzer A, Safanda M, et al. Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. Support Care Cancer. 2020;28(4):1855–65.

62. Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporosis Int. 2020;31(6):1019–21.

63. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63(3):192–7.

64. Barrett-Connor E, Swern AS, Hustad CM, et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int. 2012;23(1):233–45.

65. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654–61.

66. Chesnut CHIII, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–9.

67. Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract. 2010;64(6):821–6.

68. Baker L, Meldrum KK, Wang M, et al. The role of estrogen in cardiovascular disease. J Surg Res. 2003;115(2):325–44.

69. Cummings SR, Lui LY, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med. 2019;179(11):1491–500.

70. Diker-Cohen T, Rosenberg D, Avni T, Shepshelovich D, Tsvetov G, Gafter-Gvili A. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz322.